 Gentronix Signs Three Year Agreement with GlaxoSmithKline for GreenScreen HC and BlueScreen HC Genotoxicity Assays
04 Mar 2010 Gentronix Limited announced today that it has entered into a three year agreement with GlaxoSmithKline (GSK) to provide GreenScreen HC and BlueScreen HC genotoxicity assays for use by GSK in genotoxicity screening. This agreement extends the existing relationship between Gentronix and GSK in respect of GreenScreen HC, to include the use by GSK of BlueScreen HC in 384 well format, the latest Gentronix human cell reporter-based assay for compound profiling. GreenScreen HC was the first human cell-based assay technology that combined high sensitivity for detecting genotoxic chemicals with high specificity for reducing false positive results. This assay gives rapid results, provides additional data for safety profiling and consumes very low quantities of compound. BlueScreen HC is the new Luciferase based assay that combines all of the at...
|
|
